RSS-Feed abonnieren
DOI: 10.1055/s-0038-1651575
The Genetic Defect of Type I von Willebrand Disease “Vicenza” Is Linked to the von Willebrand Factor Gene
Publikationsverlauf
Received 13. April 1992
Accepted after revision 23. September 1992
Publikationsdatum:
03. Juli 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/199302/lookinside/thumbnails/10-1055-s-0038-1651575-1.jpg)
Summary
Type I von Willebrand disease (vWD) Vicenza is a rare variant with autosomal dominant transmission, characterized by the presence of supranormal von Willebrand factor (vWF) multimers in plasma, similar to those normally found in endothelial cells and megakaryocytes. The patients have very low levels of plasma vWF contrasting with a mild bleeding tendency. The pathophysiology of this subtype is still unknown. The presence of supranormal multimers in the patients’ plasma could be due to a mutation in the vWF molecule which affects post-translational processing, or to a defect in the cells’ processing machinery, independent of the vWF molecule. In order to determne if type I vWD Vicenza is linked to the vWF gene, we studied six polymorphic systems identified within the vWF gene in two apparently unrelated families with type I vWD Vicenza. The results of this study indicate a linkage between vWF gene and the type I vWD Vicenza trait. This strongly suggests that type I vWD Vicenza is due to a mutation in one of the vWF alleles, which results in an abnormal vWF molecule that is processed to a lesser extent than normal vWF.
-
References
- 1 Sadler JE. Von Willebrand disease. In: The Metabolie Basis of Inherited Disease. 6.. Scriver CR, Beaudet AL, Sly WS, Valle D. (eds) McGraw-Hill Book Co.; New York: 1989: 2171-2188
- 2 Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-246
- 3 Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand’s disease subtypes. Blood 1982; 59: 1272-1279
- 4 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69: 454-459
- 5 Mannucci PM, Lombardi R, Castaman G, Dent JA, Lattuada A, Rodeghiero F, Zimmerman TS. Von Willebrand disease “Vicenza” with larger-than-normal (supranormal) von Willebrand factor multimers. Blood 1988; 71: 65-70
- 6 Ginsburg D, Handin RT, Bonthron DT, Donlon TA, Bruns GAP, Latt SA, Orkin SH. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228: 1401-1406
- 7 Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW. Cloning and characterization of two cDNA coding for human von Willebrand factor. Proc Natl Acad Sci USA 1985; 82: 6394-6398
- 8 Verweij CL, de Vries CJM, Distel B, van Zonneveld A-J, Geurts van KesselA, van Mourik JA, Pannekoek H. Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucl Acid Res 1985; 13: 4699-4717
- 9 Verweij CL, Quadt R, Briët E, Dubbeldam K, van Ommen GB, Pannekoek H. Genetic linkage of two intragenic restriction fragment length polymorphisms with von Willebrand’s disease type II A. J Clin Invest 1988; 81: 1116-1121
- 10 Sampietro M, Camerino G, Romano M, Cappellini MD, Fiorelli G, Brambati B, Guerneri S, Ferrari M, Travi M, Krachmalnicoff A, Mannucci PM. Combined use of DNA probes in first trimester prenatal diagnosis of hemophilia A. Thromb Haemostas 1987; 58: 988-992
- 11 Shelton-Inloes BB, Chebab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest 1989; 79: 1459-1465
- 12 Bernardi F, Guerra S, Patracchini P, Volinia S, Buzzoni D, Ballerini G, Casonato A, Marchetti G. Von Willebrand disease investigated by two novel RFLPs. Br J Haematol 1988; 68: 243-248
- 13 Quadt R, Verweij CL, de Vries CJM, Briët E, Pannekoek H. A polymorphic Xba I site within the human von Willebrand factor (vWF) gene. Nucl Acids Res 1986; 14: 7139
- 14 Lavergne J-M, Bahnak BR, Verweij CL, Pannekoek H, Meyer D. A second Xba polymorphic site within the human von Willebrand factor (vWF) gene. Nucl Acids Res 1987; 15: 9099
- 15 Verweij CL, Hofker H, Quadt R, Briët E, Pannekoek H. RFLP for human von Willebrand factor (vWF) cDNA clone, pvWF1100. Nucl Acids Res 1985; 13: 8289
- 16 Peake IR, Liddell MB, Moodie P, Standen G, Mancuso DJ, Tuley EA, Westfield LA, Sorace JM, Sadler JE, Verweij CL, Bloom AL. Severe type III von Willebrand’s disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual. Blood 1990; 75: 654-661
- 17 Mercier B, Gaucher C, Mazurier C. A multi-allelic polymorphism of the von Willebrand factor gene detected by PCR: characterization of 94 alleles in 101 unrelated individuals. Nucl Acids Res 1991; 19: 4800
- 18 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor multimers and unusually large vWF forms derived from endothelial cells in shear stress induced platelet aggregation. J Clin Invest 1986; 78: 1456-1461